Evidence map›Paper›PMID 36232335›Full record

ArticleInternational journal of molecular sciences2022

Immune State Conversion of the Mesenteric Lymph Node in a Mouse Breast Cancer Model.

Tsukasa Shigehiro, Maho Ueno, Mayumi Kijihira, Ryotaro Takahashi, Chiho Umemura, Eman A Taha, Chisaki Kurosaka, Megumi Asayama, Hiroshi Murakami, Ayano Satoh and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Tsukasa ShigehiroResearch Institute for Biomedical Sciences, Tokyo University of Science, Chiba 278-0022, Japan.ORCID 0000-0002-5286-5108
Maho UenoDepartment of Applied Chemistry and Biotechnology, Faculty of Engineering, Okayama University, Okayama 700-8530, Japan.
Mayumi KijihiraDepartment of Applied Chemistry and Biotechnology, Faculty of Engineering, Okayama University, Okayama 700-8530, Japan.
Ryotaro TakahashiGraduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama 700-8530, Japan.
Chiho UmemuraDivision of Medical Bioengineering, Graduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan.
Eman A TahaDivision of Medical Bioengineering, Graduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan.
Chisaki KurosakaDepartment of Applied Chemistry and Biotechnology, Faculty of Engineering, Okayama University, Okayama 700-8530, Japan.
Megumi AsayamaDepartment of Applied Chemistry and Biotechnology, Faculty of Engineering, Okayama University, Okayama 700-8530, Japan.
Hiroshi MurakamiGraduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama 700-8530, Japan.
Ayano SatohGraduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama 700-8530, Japan.ORCID 0000-0003-3736-1283
Yoshimasa NakamuraGraduate School of Environmental and Life Science, Okayama University, Okayama 700-8530, Japan.ORCID 0000-0001-6606-9105
Junichiro FutamiGraduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama 700-8530, Japan.ORCID 0000-0002-0020-2855
Junko MasudaGraduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama 700-8530, Japan.ORCID 0000-0001-5066-3804
Okayama University · JPRoswell Park Comprehensive Cancer Center · US

Funding

Asahi Group Foundation N/AJapan Society for the Promotion of Science 19K0589401Japan Society for the Promotion of Science 20H02933Japan Society for the Promotion of Science 20K22857Japan Society for the Promotion of Science 21K16277,Ryobi Teien Memory Foundation N/ATOBE MAKI Scholarship Foundation N/AToyo Food Fundation N/AUrakami Food and Food Culture Promotion Foundation N/AWesco (Japan) N/A
6 · The paper itself

Abstract

Secondary lymphoid tissues, such as the spleen and lymph nodes (LNs), contribute to breast cancer development and metastasis in both anti- and pro-tumoral directions. Although secondary lymphoid tissues have been extensively studied, very little is known about the immune conversion in mesenteric LNs (mLNs) during breast cancer development. Here, we demonstrate inflammatory immune conversion of mLNs in a metastatic 4T1 breast cancer model. Splenic T cells were significantly decreased and continuously suppressed IFN-γ production during tumor development, while myeloid-derived suppressor cells (MDSCs) were dramatically enriched. However, T cell numbers in the mLN did not decrease, and the MDSCs only moderately increased. T cells in the mLN exhibited conversion from a pro-inflammatory state with high IFN-γ expression to an anti-inflammatory state with high expression of IL-4 and IL-10 in early- to late-stages of breast cancer development. Interestingly, increased migration of CD103

Indexed as

Breast NeoplasmsInterleukin-10NeoplasmsAnimalsDendritic CellsGlucansInterleukin-4Lymph NodesMiceGlucansInterleukin-10Interleukin-4breast cancer cellsdendritic cellsmesenteric lymph nodemyeloid-derived suppressor cells

Identifiers

PMID36232335
PMCPMC9570492
OpenAlexW4296480813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.